Search starts for next EMA executive director
This article was originally published in RAJ Devices
The search is formally on for the next head of the European Medicines Agency. A vacancy notice for an executive director of the agency, to take office on 1 January 2011 after the departure of Thomas Lönngren at the end of this year, was advertised on 15 January1.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib